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Introductory Chapter: Perspectives 




Acute diarrhoea is defined as frequent passage of loose or watery stools mixed 
with mucus and causes morbidity and mortality particularly in children. The 
scope of the book is to present information on acute diarrhoeal diseases in relation 
to clinical features, dehydration, management and prevention. When the stool 
contains blood, it is called dysentery. Acute diarrhoea is an ancient problem with 
tremendous public health significance. Acute diarrhoeal diseases comprise of acute 
watery diarrhoea and acute bloody diarrhoea (dysentery). The prototype of acute 
watery diarrhoea is cholera, while the same for dysentery is shigellosis. It caused 
extensive epidemics during flood, famine, war and earthquake when large number 
of people is shifted to refugee camps.
2. Disease burden
According to an estimate [1] by the World Health Organization, 3–5 million 
cholera and cholera-like cases occur worldwide, and 100,000–120,000 million cases 
die with a case-fatality rate of 2.25% (range 1–10%). This figure is actually grossly 
underestimated, because of under-reporting. These diseases, under the overarching 
syndrome of acute diarrhoea, cause tremendous pressure on the healthcare delivery 
system, and during epidemics and pandemics, this is compounded as a real public 
health problem. There have been seven pandemics (epidemic all over the world) of 
cholera which spread to more than 102 countries worldwide and killed millions of 
people.
3. New strain Vibrio cholerae O139
An unprecedented happening occurred in the epidemiology of acute diarrhoea 
[2] when a novel strain of Vibrio cholerae non O1 was found to produce an exotoxin 
akin to cholera toxin and caused large-scale epidemics. The stain was named as 
Vibrio cholerae non O139 Bengal because the strains were isolated from the coastal 
region of the Bay of Bengal. The disease caused by this stain was indistinguishable 
from O1 cholera. The same strain of Vibrio was isolated from the UK, Germany, the 
Netherlands, Nepal, Bhutan, Indonesia and Japan. This was thought to be the begin-
ning of eight cholera pandemic, but this actually did not happen so.
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4. Etiology
Acute watery diarrhoea comprises of about 20–25 pathogens which fall under 
the categories of bacterial, viral and parasitic agents. The bacterial pathogens caus-
ing diarrhoea include Vibrio cholerae O1 and O139, enterotoxigenic Escherichia coli, 
Vibrio parahaemolyticus and Salmonella; the viral pathogens include Rotavirus and 
Norwalk virus; the parasitic agents include Entamoeba histolytica, Giardia lamblia 
and Cryptosporidium. Shigella and Campylobacter jejuni cause dysentery. Rotavirus 
is a diarrhoeal disease, which affects children aged between 6 months and 2 years. 
Early vomiting is an important symptom of Rotavirus diarrhoea. Children suffering 
from Rotavirus diarrhoea occupy about 40% of beds in a children hospital.
5. Cholera toxin and dehydration
Vibrio cholerae O1 and O139 produce an exotoxin known as cholera toxin (CT) 
[2]. CT attaches to gut mucosa and helps in outpouring of fluid and electrolytes, 
and when the fluid loss exceeds the absorbing capacity of the colon, watery diar-
rhoea ensues. This leads to a condition called dehydration. Classically, dehydration 
is categorized as mild, moderate and severe dehydration. Other scoring methods of 
dehydration have been proposed and will be useful.
6. Management
The treatment of acute diarrhoea is based on the correction of fluid deficit and 
replacement of ongoing loses. Mild and moderate dehydration can be corrected by 
oral rehydration therapy [3–6] using oral rehydration salt solution. On the other 
hand, intravenous fluid is required for the management of severe dehydration. The 
WHO recommended ORS containing sodium chloride of 2.5 g, potassium chloride 
of 1.5 g, sodium bicarbonate of 2.9 g and glucose of 20 g dissolved in 1 L of drinking 
water. ORS is given slowly particularly in children. If vomiting occurs, one has to 
wait 5–10 minutes and again start giving ORS very slowly. Recently, hypo-osmolar 
ORS has been recommended. On the clinical aspect of acute diarrhoea, new scoring 
method has been suggested. It has been reported that epileptic seizures are a mani-
festation of acute diarrhoea. This is a new area where lots of research may be done.
7. Role of antibiotics
Antibiotics are used in the treatment of acute diarrhoea only for severe cholera 
and shigellosis. Antibiotic therapy reduces the duration of diarrhoea/dysentery and 
hastens recovery. The antibiotics of choice for cholera are tetracycline or single dose 
(300 mg) of doxycycline. Norfloxacin and ciprofloxacin are effective. Herbal medi-
cines may be effective in the treatment of acute diarrhoea. This mode of therapy 
will be cheap and safe.
8. Drug resistance
Drug-resistant strains of Vibrio cholerae have been reported. Shigellosis is 
treated by various antibiotics including ampicillin, co-trimoxazole, and the 
fluoroquinolone. However, multiple drug resistance is a huge problem and poses 
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as a therapeutic challenge. The drug resistance is particularly seen in Shigella 
dysenteriae type 1 strains. These strains produced large-scale sporadic, epidemics 
and pandemic. The drug-resistant shigellosis epidemic that occurred in Bangladesh 
and Central America caused large morbidity and mortality. A number of com-
plications have been reported in association with S. dysenteriae type 1 including 
hemolytic uremic syndrome (HUS) characterized by hemolysis, renal failure and 
thrombocytopenia.
9. Prevention
Prevention of acute diarrhoea is a formidable challenge. These include sanita-
tion, safe water and handwashing. Vaccination is an attractive disease prevention 
strategy. Health education plays a crucial role in the adoption of the strategy, 
particularly handwashing. This should start at the preschool level to form a habit 
in later life. Vaccination is an attractive disease prevention strategy. Recently, an 
oral cholera vaccine has been developed which has been found to protect up to 66% 
people among those vaccinated [7]. Vaccines against Rotavirus are available.
10. Final words
Finally, this book comprises of chapters of topics, which have significance in 
relation to clinical feature, dehydration, and management and prevention of acute 
diarrhoea. The reader will find the topics new, informative, and interesting.
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